Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

75.79USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$75.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
210,788
52-wk High
$82.06
52-wk Low
$20.39

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Sep '17 0.00 -1.860
Jun '17 0.00 -1.918
Mar '17 0.00 -1.797
FY 2016 Dec '16 0.00 -1.284
Sep '16 0.00 -0.772
Jun '16 0.00 -0.623
Mar '16 0.00 -0.647
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Mar-18 4 0.00 0.00 0.00 --
Quarter Ending Jun-18 4 0.00 0.00 0.00 --
Year Ending Dec-18 9 35.56 220.00 0.00 15.62
Earnings (per share)
Quarter Ending Mar-18 6 -1.74 -1.39 -2.03 --
Quarter Ending Jun-18 6 -1.75 -1.39 -2.03 --
Year Ending Dec-18 12 -5.82 1.89 -8.54 -4.44
LT Growth Rate (%) 1 26.60 26.60 26.60 --
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 180.40 35.76
P/E High - Last 5 Yrs. -- 281.08 46.66
P/E Low - Last 5 Yrs. -- 92.01 24.18
Beta 2.51 0.81 0.81
Price to Sales (TTM) -- 141.46 8.59
Price to Book (MRQ) 8.15 19.13 5.23
Price to Tangible Book (MRQ) 8.12 25.71 6.37
Price to Cash Flow (TTM) -- 120.28 26.13
% Owned Institutions -- 12.01 2.31

Dividends

  Company industry sector
Dividend Yield -- 0.29 1.50
Dividend Yield - 5 Year Avg -- 0.20 2.01
Dividend 5 Year Growth Rate -- 1.84 5.25
Payout Ratio(TTM) -- 8.47 44.77

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -- 43.81 9.62
Sales (TTM) vs TTM 1 Yr. Ago -- 45.25 7.31
Sales - 5 Yr. Growth Rate -- 32.48 10.20
EPS (MRQ) vs Qtr. 1 Yr. Ago -12.45 6.77 18.60
EPS (TTM) vs TTM 1 Yr. Ago -111.06 -- --
EPS - 5 Yr. Growth Rate -- 45.74 11.47
Capital Spending - 5 Yr. Growth Rate 22.89 41.90 14.75

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 1.77 2.43
Current Ratio (MRQ) 6.15 6.14 3.39
LT Debt to Equity (MRQ) 0.00 16.68 11.95
Total Debt to Equity (MRQ) 0.43 18.86 15.32
Interest Coverage (TTM) -202.53 -165.00 38.67

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -- 50.66 54.89
Gross Margin - 5 Yr. Avg. -- 55.48 52.59
EBITD Margin (TTM) -- -- --
EBITD - 5 Yr. Avg -- -563.40 10.03
Operating Margin (TTM) -- -589.85 2.96
Operating Margin - 5 Yr. Avg. -- -584.40 5.27
Pre-Tax Margin (TTM) -- -559.39 3.78
Pre-Tax Margin - 5 Yr. Avg. -- -592.51 5.53
Net Profit Margin (TTM) -- -554.46 0.26
Net Profit Margin - 5 Yr. Avg. -- -596.29 1.79
Effective Tax Rate (TTM) -- -0.06 22.06
Effective Tax Rate - 5 Yr. Avg. -- 17.84 24.20

Efficiency

  Company industry sector
Revenue/Employee (TTM) 0 23,379,765 824,372,705
Net Income/Employee (TTM) -2,929,614 -413,169 96,444,553
Receivable Turnover (TTM) -- 14.82 5.41
Inventory Turnover (TTM) -- 2.46 3.49
Asset Turnover (TTM) 0.00 0.39 0.90

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -63.85 -0.92 10.73
Return on Assets - 5 Yr. Avg. -39.14 -0.52 12.02
Return on Investment (TTM) -70.41 -0.52 13.59
Return on Investment - 5 Yr. Avg. -41.73 2.04 15.73
Return on Equity (TTM) -70.56 -3.30 15.20
Return on Equity - 5 Yr. Avg. -42.93 -2.17 16.95
  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -109.79 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Esperion Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -2.95 -0.18 99 61
13 Week 52.31 43.76 99 91
26 Week 67.46 48.66 99 87
52 Week 223.07 177.55 99 88
YTD 13.79 11.35 99 91
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 0.00%
# of Holders: 218
Total Shares Held: 26,304,703
3 Mo. Net Change: -1,333,506
# New Positions: 43
# Closed Positions: 28
# Increased Positions: 113
# Reduced Positions: 92
# Net Buyers: 21
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.